Day: January 5, 2022

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) — TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that Garry Menzel, President and Chief Executive Officer of TCR² Therapeutics, will present an update on Company progress at the H.C. Wainwright BioConnect Conference on Monday, January 10th at 7:00AM E.T. using a virtual platform. A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation. About TCR² Therapeutics TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for cancer patients suffering...

EEZY PLC — STOCK EXCHANGE RELEASE — 5 JANUARY 2022 AT 13.45 Eezy Plc: Notification of change in holdings – Evli Bank Eezy Plc has received on 5 January 2022 a notification, pursuant to Chapter 9, Section 5 of the Finnish Securities Market Act, from Evli Bank Plc, according to which their total holding of shares in Eezy Plc has exceeded 5 % on 4 January 2022.  Evli Bank Plc owns 100% of Evli Rahastoyhtiö Oy that manages the Evli Suomi Pienyhtiöt fund. Evli Bank Plc’s total ownership of Eezy Plc’s shares and votes according to the notification:   % ofshares and voting rights % ofshares and voting rights through financial instruments Total of both in % Total number of shares and voting rights of issuerResulting situation on the date on which threshold was crossed or reached 5.48 % 0 5.48 % 25 046 815Position...

Third mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for shingles, a debilitating, disfiguring and painful disease that affects people all over the world Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology Clinical trials are expected to start in the second half of 2022 BioNTech will receive $225 million upfront, including an upfront cash payment of $75 million and an equity investment of $150 million, and will be eligible to receive future approval and sales milestone payments totaling up to $200 million as well as a share of gross profits arising from future product sales Pfizer will receive an upfront payment of $25 million from BioNTech for its proprietary antigen sequences identified by PfizerNEW YORK and MAINZ,...

DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer Michael Castagna, PharmD, will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022. Interested parties can access a link to the on demand webcast of the presentation from the Events & Presentations section of the Company’s website at https://investors.mannkindcorp.com/events-and-presentations. The webcast replay may be accessed at the same location for 14 days. About MannKind CorporationMannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic...

MannKind purchased an additional convertible note issued by Thirona Bio Nonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022 MannKind’s CEO appointed as a member of the Thirona board of directorsDANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. (“Thirona”) with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors. Under the terms of the collaboration, which began in June 2021, the companies are evaluating the therapeutic potential of Thirona’s locally acting...

Municipality Finance PlcStock Exchange Release5 January 2022 at 1:00 pm (EET)  Municipality Finance Group Financial calendar in 2022 In this stock exchange release, MuniFin Group provides its financial calendar for 2022. The calendar includes the planned publication dates of MuniFin Group’s financial reports. The financial statements of MuniFin Group for the year 2021 will be published on 4 February 2022. The annual report 2021 will be published around 3 March 2022. On the same date, MuniFin Group will also publish the Pillar III disclosure based on the Capital Requirements Regulation and the Corporate Governance Statement. The half year report for the period 1 January–30 June 2022 will be published on 5 August 2022. The financial reports are published in English and in Finnish. The Annual General Meeting of Municipality Finance Plc...

CHERRY HILL, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) — The Real Good Food Company, Inc. (Nasdaq: RGF) (“Real Good Foods” or the “Company”), a health- and wellness-focused frozen food company, today announced management will present at the 2022 ICR Conference on Tuesday, January 11, 2022. The presentation is scheduled to begin at 3:00 p.m. ET. The webcast will be available on the “Investors” section of the Company’s website at www.realgoodfoods.com, and will be archived online through Tuesday, February 8, 2022. About The Real Good Food Company Founded in 2016, Real Good Foods believes there is a better way to enjoy our favorite foods. Its brand commitment, “Real Food You Feel Good About Eating,” represents the Company’s strong belief that, by eating its food, consumers can enjoy more of their favorite foods and, by doing so, live better...

VANCOUVER, B.C., Jan. 05, 2022 (GLOBE NEWSWIRE) — Fobi AI Inc. (FOBI: TSXV FOBIF: OTCQB) (the “Company” or “FOBI”), a leader in providing real-time data analytics through artificial intelligence to drive operational efficiencies and profitability is pleased to announce that the company has signed an annual license with an auto-renewal with one of the world’s leading insurance providers. Fobi earns revenue from this deal through an annual license fee as well a license fee per Wallet pass issued, generating monthly recurring revenue. FOBI WALLET PASS POWERS DIGITAL PROOF OF INSURANCE FOR THREE OF THE TOP TEN LARGEST GLOBAL INSURANCE COMPANIES Fobi’s Wallet pass platform will now enable the insurance provider to issue digital proof of insurance passes for both auto insurance and general insurance across five countries in Europe....

SHANGHAI, China and SINGAPORE, Jan. 05, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biociences Co., Ltd (“Junshi Biosciences”, HKEX: 1877, SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and DotBio Pte. Ltd (“DotBio”), a biotech company specialized in next generation antibody therapies, announced today that they have entered into a collaboration to develop next-generation antibody therapies. Junshi Biosciences will obtain the license to one of DotBio’s DotBody modules, to be used within the oncology field for the development of several multi-specific antibodies. DotBio will be entitled to upfront and milestone payments, as well as royalties as the molecules progress through clinical development, regulatory approvals, and commercialization. DotBio’s...